The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
2022: Accelerated Therapeutics Program, 2022Using Small Molecules that Modulate Mitochondrial Function for the Treatment of Parkinson's Disease
Study Rationale: Dysfunction in energy-producing structures called mitochondria is a crucial driver of the initiation and progression of Parkinson’s disease (PD). Mitochondria in the cells of people...
-
Research Grant, 2022Objectively Measuring the Severity of Vocal and Speech-related Symptoms Associated with Parkinson’s Disease
Study Rationale: The ability to objectively measure vocal symptoms is necessary to better characterize the emergence and development of speech deficits, particularly in the early phases of Parkinson’s...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Digital Detection of Alpha-synuclein Aggregates for the Quantitative Diagnosis of Parkinson’s disease
Study Rationale: The detection of protein aggregates is currently at the leading edge of diagnostic developments in Parkinson’s disease and other age-related disorders. There is demand for...
-
Research Grant, 2022Development And Validation Of A Miro1 Biomarker Assay Using White Blood Cells
Study Rationale: The mitochondrial protein Miro1 fails to be degraded and this defect impairs mitophagy in more than 90% of all Parkinson’s disease (PD) patients of both genetic and sporadic forms...
-
Spring 2022 RFP: Expanding Biological Understanding of Parkinson's Disease, 2022The Role of Acid Ceramidase in GBA1 in Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene are one of the most common risk factor for Parkinson’s disease (PD). GBA1 encodes glucocerebrosidase, an enzyme that breaks down a lipid called...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Using AZP2006 (Ezeprogind) to Stabilize Progranulin – A Novel Therapeutic Strategy for GBA1-linked Parkinson’s Disease
Study Rationale: Progranulin (PGRN) regulates cell growth, survival and changes. They are usually secreted or transported to the lysosome. Its deficiency and inflammation leads to a decline in the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.